Programmed Intermittent Epidural Bolus for Labor Analgesia During First Stage of Labor

Sponsor
Samuel Lunenfeld Research Institute, Mount Sinai Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT02550262
Collaborator
(none)
40
1
4
3
13.4

Study Details

Study Description

Brief Summary

Until recently, at Mount Sinai Hospital, epidural analgesia for labor pain was delivered with a pump that could only provide continuous infusion of the freezing medication in combination of pushes of medication activated by the patient, a technique called patient controlled epidural analgesia (PCEA). In the last decade or so, the literature has suggested that this continuous infusion of medication is not as effective as previously thought, and suggested that instead of continuous infusion, intermittent programmed pushes should be used. The investigators now have devices that are able to do that. Programmed intermittent epidural bolus (PIEB) is a new technological advance based on the concept that boluses of freezing medication in the epidural space are superior to continuous epidural infusion (CEI). The new pumps are able to deliver bolus of medication at regular intervals (PIEB), in addition to what the patient can deliver herself (PCEA). Studies have shown that delivering analgesia in this manner can prolong the duration of analgesia, diminish motor block, lower the incidence of breakthrough pain, improve maternal satisfaction and decrease local anesthetic consumption. Based on the information already available in the literature, this study aims to determine the best regimen of PIEB achievable with our standard epidural mixture.

The hypothesis of this study is that there is an optimal interval time between PIEB boluses of 30 to 60 minutes at a fixed volume of 10 ml of our standard epidural mixture that will provide women the necessary drug requirements, thus avoiding breakthrough pain and need for PCEA or physician intervention.

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

All studies involving PIEB to date have provided an analgesic regimen that delivered an amount of local anesthetic that was below the patient's requirement per hour, as the studies were done in the context of an association with PCEA (Patient controlled epidural anesthesia) as a rescue technique. As a result, PCEA requests were frequent and therefore these studies have not been able to truly understand the pharmacology of the bolus technique in the PIEB regimen, as the PCEA utilized by patients added an extra component to the regimen.

The ideal volume and interval time between PIEB bolus has not yet been established in the literature. Most likely the ideal volume and interval time between PIEB bolus will be specific for each epidural mixture.

At Mount Sinai Hospital, PIEB devices have been recently introduced. Currently our standard epidural mixture is bupivacaine 0.0625% with fentanyl 2mcg/ml. Our current epidural regimen consists of 10 ml continuous infusion per hour, with PCEA boluses of 5 ml and a lock out interval of 10 minutes, for a maximum of 20 ml of the epidural mixture per hour. In this study, the investigators will offer patients 10mL PIEBs of bupivacaine 0.0625% with fentanyl 2mcg/ml at 4 different intervals. PCEA bolus of 5mL of the same solution will also be available. The goal is to establish the ideal PIEB regimen that will be effective for our patient population with our standard epidural mixture.

Finding the best way of using the new device that will be able to provide analgesia for 90% of the parturients will represent a great improvement in labor analgesia. Moreover, there are expectations of having fewer side effects since the PIEB is more effective than CEI.

Study Design

Study Type:
Interventional
Actual Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Programmed Intermittent Epidural Bolus for Labor Analgesia During First Stage of Labor: A Sequential Allocation Trial to Determine the Optimum Interval Time Between Boluses of a Fixed Volume of 10 ml of Bupivacaine 0.0625% Plus Fentanyl 2 mcg/ml.
Study Start Date :
Sep 1, 2015
Actual Primary Completion Date :
Dec 1, 2015
Actual Study Completion Date :
Dec 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Experimental: 60 minutes

The infusion pump will deliver programmed intermittent epidural boluses at a 60-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.

Drug: Bupivacaine
0.0625% Bupivacaine plus fentanyl 2mcg/ml
Other Names:
  • Marcaine
  • Drug: Fentanyl
    0.0625% Bupivacaine plus fentanyl 2mcg/ml

    Device: Infusion pump
    Infusion pump set to deliver programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).
    Other Names:
  • CADD-Solis Ambulatory Infusion Pump
  • Experimental: 50 minutes

    The infusion pump will deliver programmed intermittent epidural boluses at a 50-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.

    Drug: Bupivacaine
    0.0625% Bupivacaine plus fentanyl 2mcg/ml
    Other Names:
  • Marcaine
  • Drug: Fentanyl
    0.0625% Bupivacaine plus fentanyl 2mcg/ml

    Device: Infusion pump
    Infusion pump set to deliver programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).
    Other Names:
  • CADD-Solis Ambulatory Infusion Pump
  • Experimental: 40 minutes

    The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.

    Drug: Bupivacaine
    0.0625% Bupivacaine plus fentanyl 2mcg/ml
    Other Names:
  • Marcaine
  • Drug: Fentanyl
    0.0625% Bupivacaine plus fentanyl 2mcg/ml

    Device: Infusion pump
    Infusion pump set to deliver programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).
    Other Names:
  • CADD-Solis Ambulatory Infusion Pump
  • Experimental: 30 minutes

    The infusion pump will deliver programmed intermittent epidural boluses at a 30-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.

    Drug: Bupivacaine
    0.0625% Bupivacaine plus fentanyl 2mcg/ml
    Other Names:
  • Marcaine
  • Drug: Fentanyl
    0.0625% Bupivacaine plus fentanyl 2mcg/ml

    Device: Infusion pump
    Infusion pump set to deliver programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).
    Other Names:
  • CADD-Solis Ambulatory Infusion Pump
  • Outcome Measures

    Primary Outcome Measures

    1. No request for supplemental analgesia [6 hours]

      No request for supplemental analgesia (PCEA bolus or clinician administered bolus) until the completion of the first stage of labor or until 6 hours following initiation of the programmed intermittent epidural bolus (PIEB).

    Secondary Outcome Measures

    1. Sensory block level [6 hours]

      Sensory block to ice will be assessed bilaterally at the mid axillary lines, and the level of block will be the level at which the patient still does not feel cold sensation as compared to a control site (frontal part of the head)

    2. Motor block level assessed using Bromage score [6 hours]

      Motor block will be assessed with the Bromage score: 0 = able to raise the extended leg; 1 = unable to raise the extended leg but able to flex knees; 2 = unable to flex knees, but able to flex ankle; 3 = unable to flex ankle.

    3. Hypotension [6 hours]

      A decrease in systolic blood pressure greater than 20% from baseline (defined as an average of 3 readings prior to epidural).

    4. Pain score [6 hours]

      Pain score measured hourly using VNRS (0-10)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 55 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • ASA I or II

    • Full term (≥ 37 weeks gestation)

    • nulliparous

    • Singleton pregnancy, vertex presentation

    • Regular painful contractions occurring at least every 5 minutes

    • VAS Pain score at requesting analgesia > 5 (VNPS 0-10)

    • Cervical dilatation < 5 cm

    Exclusion Criteria:
    • Refusal to provide written informed consent.

    • Any contraindication to epidural anesthesia

    • Accidental dural puncture

    • Allergy or hypersensitivity to bupivacaine or fentanyl

    • Use of opioids or sedatives within the last 4 hours.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Mount Sinai Hospital Toronto Ontario Canada M5G1X5

    Sponsors and Collaborators

    • Samuel Lunenfeld Research Institute, Mount Sinai Hospital

    Investigators

    • Principal Investigator: Jose CA Carvalho, MD, MOUNT SINAI HOSPITAL

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital
    ClinicalTrials.gov Identifier:
    NCT02550262
    Other Study ID Numbers:
    • 15-01
    First Posted:
    Sep 15, 2015
    Last Update Posted:
    May 3, 2016
    Last Verified:
    May 1, 2016
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Keywords provided by Samuel Lunenfeld Research Institute, Mount Sinai Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 3, 2016